Jasper Therapeutics Ownership

JSPR Stock  USD 3.33  0.04  1.19%   
Jasper Therapeutics has a total of 15.02 Million outstanding shares. The majority of Jasper Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Jasper Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Jasper Therapeutics. Please pay attention to any change in the institutional holdings of Jasper Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.

Jasper Stock Ownership Analysis

About 88.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.18. Some equities with similar Price to Book (P/B) outperform the market in the long run. Jasper Therapeutics recorded a loss per share of 5.27. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 4th of January 2024. Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Jasper Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 35 people. To learn more about Jasper Therapeutics call Ronald Martell at 650 549 1400 or check out https://jaspertx.com.

Jasper Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Jasper Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Jasper Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Jasper Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Tucker Edwin Jonathan over a month ago
Acquisition by Tucker Edwin Jonathan of 90000 shares of Jasper Therapeutics at 6.0 subject to Rule 16b-3
 
Klein Lawrence Otto over three months ago
Acquisition by Klein Lawrence Otto of 78045 shares of Jasper Therapeutics at 3.54 subject to Rule 16b-3
 
Kapoor Vishal over three months ago
Acquisition by Kapoor Vishal of 47000 shares of Jasper Therapeutics at 1.6 subject to Rule 16b-3
 
Mahal Jeetinder Singh over six months ago
Disposition of 900 shares by Mahal Jeetinder Singh of Jasper Therapeutics at 24.155 subject to Rule 16b-3
 
Mahal Jeetinder Singh over six months ago
Acquisition by Mahal Jeetinder Singh of 900 shares of Jasper Therapeutics at 7.1 subject to Rule 16b-3
 
Martell Ron over six months ago
Disposition of 87531 shares by Martell Ron of Jasper Therapeutics at 1.46 subject to Rule 16b-3
 
Mahal Jeetinder Singh over six months ago
Acquisition by Mahal Jeetinder Singh of 900 shares of Jasper Therapeutics at 7.1 subject to Rule 16b-3
 
Martell Ron over six months ago
Disposition of 87531 shares by Martell Ron of Jasper Therapeutics at 1.46 subject to Rule 16b-3
 
Carlyle Group Inc. over six months ago
Discretionary transaction by Carlyle Group Inc. of 78045 shares of Jasper Therapeutics at 3.54 subject to Rule 16b-3
 
Lis William over a year ago
Acquisition by Lis William of 89972 shares of Jasper Therapeutics at 3.54 subject to Rule 16b-3
 
Martell Ron over a year ago
Acquisition by Martell Ron of 10000 shares of Jasper Therapeutics at 23.95 subject to Rule 16b-3
 
Tucker Edwin Jonathan over a year ago
Acquisition by Tucker Edwin Jonathan of 400 shares of Jasper Therapeutics at 4.1735 subject to Rule 16b-3

Jasper Therapeutics Outstanding Bonds

Jasper Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Jasper Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Jasper bonds can be classified according to their maturity, which is the date when Jasper Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.